Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4
weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing
disease.
Funding Source - FDA Office of Orphan Products Development (OOPD)